Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Innovative antiviral compounds: the first effective method for treatment of enterovirus infections

Reference number
Coordinator Curovir AB
Funding from Vinnova SEK 300 000
Project duration March 2017 - July 2017
Status Completed
Venture Innovative Startups

Purpose and goal

The aim of the phase 1 project was to a) develop synthetic methods for the synthesis of substances on a larger scale, b) evaluate substances in different in vitro models and c) investigate different ADME / PK parameters for selecting a smaller number of substances for in vivo studies (the planned phase 2 project). The final goal of the phase 1 and the phase 2 project is to choose a so-called "candidate drug" for preclinical development.

Expected effects and result

We have succeeded in completing the phase 1 project as planned and the results are positive. We have identified about 10 substances that we will take to the phase 2 project (that includes toxicity studies and in-vivo in-vivo studies).

Planned approach and implementation

The project consisted of three work packages (WP): WP1 Synthesis of new substances WP2 In-vitro studies WP3 ADME/PK studies Design of new substances was based on SAR information from the previous phase of the development. Substances were synthesized and tested in a variety of assays at our lab and in collaboration with a partner. The summary of the results was made and showed that we have about 10 substances that can be used in the next phase.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 8 January 2019

Reference number 2017-00016

Page statistics